Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults

Published:2022-01-10 Issue:2 Volume:7 Page:195-199
ISSN:2058-5276
Container-title:Nature Microbiology
language:en
Short-container-title:Nat Microbiol

Author:

Romero-Olmedo Addi J.^ORCID,Schulz Axel Ronald^ORCID,Hochstätter Svenja,Das Gupta Dennis,Virta Iiris,Hirseland Heike,Staudenraus Daniel,Camara Bärbel,Münch Carina,Hefter Véronique,Sapre Siddhesh,Krähling Verena,Müller-Kräuter Helena,Widera Marek^ORCID,Mei Henrik E.,Keller Christian,Lohoff Michael^ORCID

Funder

Senatsverwaltung für Bildung, Jugend und Wissenschaft, Berlin

Deutsche Forschungsgemeinschaft

Hessisches Ministerium für Wissenschaft und Kunst

Else Kröner-Fresenius-Stiftung

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Microbiology (medical),Genetics,Applied Microbiology and Biotechnology,Immunology,Microbiology

Link

https://www.nature.com/articles/s41564-021-01046-z.pdf

Reference12 articles.

1. Haas, E. J. et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 397, 1819–1829 (2021).

2. Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).

3. Collier, D. A. et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature 596, 417–422 (2021).

4. Brosh-Nissimov, T. et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully-vaccinated hospitalized COVID-19 patients in Israel. Clin. Microbiol. Infect. https://doi.org/10.1016/j.cmi.2021.06.036 (2021).

5. Braun, J. et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature 587, 270–274 (2020).

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aging and viral evolution impair immunity against dominant pan-coronavirus-reactive T cell epitope;2024-08-21

2. Group of longitudinal adverse event patterns after the fourth dose of COVID-19 vaccination with a latent class analysis;Frontiers in Public Health;2024-07-30

3. Adjuvantation of a SARS-CoV-2 mRNA vaccine with controlled tissue-specific expression of an mRNA encoding IL-12p70;Science Translational Medicine;2024-07-24

4. Prophylactic antibodies inhibit spike‐specific T and B cell responses after COVID‐19 vaccination;Journal of Medical Virology;2024-07

5. SARS‐CoV‐2‐Spike T‐cell response after receiving one or two Wuhan‐Hu‐1‐based mRNA COVID‐19 vaccine booster doses in elderly nursing home residents;Journal of Medical Virology;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3